The Latest Breaking News on Regenxbio

The U.S. Food and Drug Administration (FDA) has accepted for review MediWound’s (NASDAQ:MDWD) recently re-submitted Biologics License Application (BLA) for…

Analysts have provided the following ratings for Regenxbio (NASDAQ:RGNX) within the last quarter:

Regenxbio (NASDAQ:RGNX) brought in sales totaling $22.22 million during Q1 according to data provided by Benzinga Pro. However, earnings decreased…

Over the past 3 months, 4 analysts have published their opinion on Regenxbio (NASDAQ:RGNX) stock. These analysts are typically employed…

What are Value Stocks? A value stock is traditionally defined in terms of how investors in the marketplace are valuing…

Regenxbio (NASDAQ:RGNX) has observed the following analyst ratings within the last quarter:

According to Benzinga Pro, during Q4, Regenxbio (NASDAQ:RGNX) earned $294.02 million, a 603.42% increase from the preceding quarter. Regenxbio also…

Over the past 3 months, 4 analysts have published their opinion on Regenxbio (NASDAQ:RGNX) stock. These analysts are typically employed…

Regenxbio (NASDAQ:RGNX) reported its Q4 earnings results on Tuesday, March 1, 2022 at 04:00 PM. Here's what investors need to…

Regenxbio (NASDAQ:RGNX) is set to give its latest quarterly earnings report on Tuesday, 2022-03-01. Here's what investors need to know…

Over the past 3 months, 4 analysts have published their opinion on Regenxbio (NASDAQ:RGNX) stock. These analysts are typically employed…